Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.
作者信息
Asou Norio, Iwanaga Eisaku, Nanri Tomoko, Mitsuya Hiroaki
出版信息
Haematologica. 2010 Sep;95(9):e1. doi: 10.3324/haematol.2010.27656.
Abstract
摘要
相似文献
1
Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.急性早幼粒细胞白血病患者中携带TEL-PDGFRB的治疗相关髓系肿瘤经低剂量甲磺酸伊马替尼成功治疗。
Haematologica. 2010 Sep;95(9):e1. doi: 10.3324/haematol.2010.27656.
2
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Leuk Lymphoma. 2014 Feb;55(2):435-8. doi: 10.3109/10428194.2013.800870. Epub 2013 Aug 5.
3
Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.采用低剂量伊马替尼单药治疗FIP1L1-PDGFRA阳性急性嗜酸性粒细胞髓性白血病，实现完全且持久的细胞学和分子学缓解。
Eur J Haematol. 2014 Jun;92(6):541-5. doi: 10.1111/ejh.12272. Epub 2014 Feb 19.
4
[Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].[基于白血病发生的基因产物靶向治疗的基础与临床研究——编者按]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Feb;13(1):1-8.
5
Morphologic heterogeneity of acute promyelocytic leukemia: therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology.急性早幼粒细胞白血病的形态学异质性：表现为FAB-M2形态的治疗相关急性早幼粒细胞白血病。
Am J Hematol. 2006 Jun;81(6):475-6. doi: 10.1002/ajh.20577.
6
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.使用极低剂量伊马替尼治疗FIP1L1-PDGFRα阳性慢性嗜酸性粒细胞白血病后的持久缓解。
Cancer Chemother Pharmacol. 2011 Apr;67(4):967-9. doi: 10.1007/s00280-011-1582-3. Epub 2011 Feb 17.
7
Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
Leuk Lymphoma. 2005 Feb;46(2):297-8. doi: 10.1080/10428190400015667.
8
Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.综合基因组分析鉴定出一种新的TNKS2-PDGFRA融合基因，该基因定义了一种对伊马替尼治疗反应显著的嗜酸性粒细胞增多性髓系肿瘤。
Blood Cancer J. 2015 Feb 6;5(2):e278. doi: 10.1038/bcj.2014.95.
9
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Int J Hematol. 2007 Feb;85(2):173-4. doi: 10.1532/IJH97.06187.
10
Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
Blood. 2003 Feb 1;101(3):1200-1. doi: 10.1182/blood-2002-09-2932.
引用本文的文献
1
-positive acute lymphoblastic leukemia following successful treatment of acute promyelocytic leukemia: case report.急性早幼粒细胞白血病成功治疗后发生的阳性急性淋巴细胞白血病：病例报告
Front Pharmacol. 2023 Jun 16;14:1141311. doi: 10.3389/fphar.2023.1141311. eCollection 2023.
2
[The study of 4 cases of myeloid neoplasm with t (5;12) (q33;p13) and the literatures review].[4例伴t(5;12)(q33;p13)的髓系肿瘤病例研究及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):302-7. doi: 10.3760/cma.j.issn.0253-2727.2016.04.011.
本文引用的文献
1
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.一项短期低剂量伊马替尼试验可快速鉴定高嗜酸性粒细胞综合征中的应答患者。
Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. Epub 2009 Sep 4.
2
Therapy related CMML: a case report and review of the literature.治疗相关的慢性粒单核细胞白血病：一例病例报告及文献综述
Int J Hematol. 2009 Jun;89(5):699-703. doi: 10.1007/s12185-009-0318-1. Epub 2009 May 9.
3
Therapy-related myeloid neoplasms.治疗相关的髓系肿瘤
Haematologica. 2009 Apr;94(4):454-9. doi: 10.3324/haematol.2008.005157.
4
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.除KIT和FLT3突变外，JAK2-V617F激活突变与t(8;21)(q22;q22)急性髓系白血病患者的临床结局相关。
Haematologica. 2009 Mar;94(3):433-5. doi: 10.3324/haematol.13283. Epub 2009 Jan 30.
5
Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).
Acta Haematol. 2008;119(1):57-9. doi: 10.1159/000115966. Epub 2008 Feb 12.
6
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.巩固治疗后PML-RARα转录本转阴的急性早幼粒细胞白血病患者接受或不接受强化维持化疗的随机研究：日本成人白血病研究组（JALSG）APL97研究
Blood. 2007 Jul 1;110(1):59-66. doi: 10.1182/blood-2006-08-043992. Epub 2007 Mar 20.
7
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.血小板衍生生长因子受体β（PDGFRB）融合基因阳性且BCR-ABL阴性的慢性骨髓增殖性疾病患者对伊马替尼的持久反应。
Blood. 2007 Jan 1;109(1):61-4. doi: 10.1182/blood-2006-05-024828. Epub 2006 Sep 7.
8
Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: monosomy 7 and t(12;17)(p13;q11.2).
Am J Hematol. 2007 Mar;82(3):248-9. doi: 10.1002/ajh.20730.
9
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.AMN107的特性，一种天然和突变型Bcr-Abl的选择性抑制剂。
Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007.
10
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.急性早幼粒细胞白血病后的骨髓增生异常综合征：欧洲急性早幼粒细胞白血病协作组的经验
Leukemia. 2003 Aug;17(8):1600-4. doi: 10.1038/sj.leu.2403034.
Zotero 插件